Samuel O'Brient

Samuel O'Brient

Expertise: Global Financial Markets, Macroeconomics and Geopolitics

Education: BA, Economics & Political Science, Sarah Lawrence College; MSc, International Politics, Trinity College Dublin

Awards & Accomplishments: Published in Curlew Quarterly. Quoted in Forbes. Interviewed by Foreign Policy.

About Samuel
Samuel O’Brient is a Reporter for InvestorPlace, where his work focuses primarily on financial markets, global economic trends, and public policy. O’Brient writes a weekly column on recent political news that investors should be following.

From his early days at InvestorPlace, O’Brient found himself drawn to the booming world of electric vehicles and green energy. His coverage of mining and other battery components has made him an expert source for industry publications. During his early years as an Economic Policy Analyst at U.S. Resist News, he gained expertise in international trade as the U.S.-China trade war dominated headlines. This in-depth research and analysis experience helped strengthen his prowess in all things political economy. O’Brient brings this expertise to work with him every day, thoughtfully analyzing how the daily happenings on the Capitol trickle down to Wall Street… and how retail investors can take action to profit.

An experienced journalist, editor, and economic policy analyst, O’Brient has spent his career guided by a deep passion for economic theory and policy. As a financial blogger on TipRanks, he has received 4.6 stars and is ranked in the top 10% of stock pickers.

O’Brient’s work on economic and tech policy has been curated by popular outlets Marker, OneZero and Gen.

He can be reached on LinkedIn and Muck Rack.

Recent Articles

Rivian Reports Surging Preorders Ahead of the Hotly Anticipated RIVN Stock IPO

Rivian is about to start trading and the EV world is watching, as is Wall Street. Here's what to keep in mind about the RIVN stock IPO.

OPEN Stock Is Under Pressure Because Zillow Just Revealed the Challenges of iBuying

As Zillow faces a grim future, Opendoor looks to gain a market share where its competitor couldn't. So far this is sending OPEN stock up.

OCGN Stock Alert: WHO Issues Emergency-Use Listing for Covaxin

The WHO has finally given Covaxin emergency approval, putting OCGN stock in the spotlight. Will Ocugen be able to bring doses to the U.S.?

SAVA Stock: 8 Things to Know as Cassava Sciences Rockets Higher

As investors bet that Cassava Sciences is on the cusp of a breakthrough with its Alzheimer's treatment, SAVA stock is gaining.

PFE Stock Alert: 3 Catalysts Giving Pfizer Stock a Shot in the Arm Today

Pfizer is getting ready to start shipping children's vaccines, and PFE stock is rising. That's not the only good news for investors, though.